Literature DB >> 21925540

Increased throughput assays of locomotor dysfunction in Drosophila larvae.

C Sinadinos1, C M Cowan, A Wyttenbach, A Mudher.   

Abstract

Larval locomotion is a sensitive readout of a range of nervous system deficits in Drosophila, and has been utilised to quantify modulation of the disease phenotype in models of human disease. Single larvae are typically analysed in series using manual quantification of parameters such as contraction rate, or grouped together and studied en-masse. Here, we describe the development of tests for the analysis of several spatially isolated third instar larvae in parallel. We rapidly quantify larval turning rate and velocity during wandering behaviour in a 4 plate assay. In a second test, larvae are recorded as they race along five parallel lanes towards a yeast stimulus. This allows increased throughput analysis of comparative genotypes simultaneously, video archiving, and detection of exacerbation or rescue of defective locomotion in a Drosophila model of tauopathy, as we demonstrate genetically and through delivery of candidate therapeutic chemicals in fly food. The tests are well-suited for rapid comparison of locomotion capability in Drosophila mutants or candidate modulation screens in Drosophila models of human disease.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21925540     DOI: 10.1016/j.jneumeth.2011.08.037

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  11 in total

1.  Optimization of wrMTrck to monitor Drosophila larval locomotor activity.

Authors:  David S Brooks; Kumar Vishal; Jessica Kawakami; Samuel Bouyain; Erika R Geisbrecht
Journal:  J Insect Physiol       Date:  2016-07-16       Impact factor: 2.354

2.  Measurement of larval activity in the Drosophila activity monitor.

Authors:  Aidan L McParland; Taylor L Follansbee; Geoffrey K Ganter
Journal:  J Vis Exp       Date:  2015-04-30       Impact factor: 1.355

3.  Hyperactive locomotion in a Drosophila model is a functional readout for the synaptic abnormalities underlying fragile X syndrome.

Authors:  Risa Kashima; Patrick L Redmond; Prajakta Ghatpande; Sougata Roy; Thomas B Kornberg; Thomas Hanke; Stefan Knapp; Giorgio Lagna; Akiko Hata
Journal:  Sci Signal       Date:  2017-05-02       Impact factor: 8.192

4.  Modelling tauopathies in Drosophila: insights from the fruit fly.

Authors:  Catherine M Cowan; Megan A Sealey; Shmma Quraishe; Marie-Therese Targett; Kristen Marcellus; Douglas Allan; Amritpal Mudher
Journal:  Int J Alzheimers Dis       Date:  2011-12-29

5.  Synaptic abnormalities in a Drosophila model of Alzheimer's disease.

Authors:  Siddhita D Mhatre; Vivek Satyasi; Mark Killen; Brie E Paddock; Robert D Moir; Aleister J Saunders; Daniel R Marenda
Journal:  Dis Model Mech       Date:  2014-01-30       Impact factor: 5.758

6.  Regulators of autophagosome formation in Drosophila muscles.

Authors:  Jonathan Zirin; Joppe Nieuwenhuis; Anastasia Samsonova; Rong Tao; Norbert Perrimon
Journal:  PLoS Genet       Date:  2015-02-18       Impact factor: 5.917

7.  FIM, a novel FTIR-based imaging method for high throughput locomotion analysis.

Authors:  Benjamin Risse; Silke Thomas; Nils Otto; Tim Löpmeier; Dimitar Valkov; Xiaoyi Jiang; Christian Klämbt
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240

8.  NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy.

Authors:  S Quraishe; C M Cowan; A Mudher
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

9.  Serotonin receptors expressed in Drosophila mushroom bodies differentially modulate larval locomotion.

Authors:  Bryon Silva; Nicolás I Goles; Rodrigo Varas; Jorge M Campusano
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

10.  Role of autophagy in glycogen breakdown and its relevance to chloroquine myopathy.

Authors:  Jonathan Zirin; Joppe Nieuwenhuis; Norbert Perrimon
Journal:  PLoS Biol       Date:  2013-11-12       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.